The FDA has agreed to investigate Bayer's Essure birth control device, following complaints of fraud during the clinical trial and dangerous side effects.
Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
Bayer is deepening its ties with Harvard and MIT's Broad Institute, delving into cardiovascular genomics in hopes of spotlighting new therapeutic approaches to deadly diseases.
The latest of nearly 5 months of speculation has Panasonic Healthcare counting on paying only $830 million for Bayer's diabetes device business it has been trying to sell off. Previous estimates had guessed a sale of up to $2.3 billion.
Bayer Korea has been ordered to divest its oral contraceptives business, chiefly its Mercilon (ethinylestradiol) drug, which it acquired when its Germany parent Bayer bought Merck's consumer-care business recently.
Bayer has already said it plans to home in on life sciences after it carves out its plastics unit later this year for an IPO or spinoff. So what, exactly, does that mean for its HealthCare division, numbers-wise?
As it prepares to streamline itself and rebrand as a life-sciences-focused company, Bayer is counting on colorectal cancer drug Stivarga to chip in to its sales haul--big time. But the drug can only go so far if people don't get checked for the lethal cancer.
Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.
Bayer Healthcare said it plans to sell its animal health production facility in St. Joseph, MO, and some of the products manufactured at the plant.
Bayer said earlier this week that it would be counting on eye blockbuster Eylea to provide some serious sales growth in 2015, and now, it has a new indication the company hopes can help it get there.